Fluocinolone Acetonide
JFDA label: Synalar-N ointment
Mechanism of Action
Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist
| Target | Action | Gene / class |
|---|---|---|
| Glucocorticoid receptor efficacy | AGONIST | NR3C1 |
Indications
Approved
- Dermatitis, Atopic — atopic eczema
- Dermatitis, Seborrheic — seborrheic dermatitis
- Eye Diseases — eye inflammation
- Hemorrhoids — hemorrhoid
- Infections — infectious disease
- Macular Edema — macular retinal edema
- Melanosis — freckles
- Psoriasis — psoriasis
- Skin Diseases — skin disease
- Uveitis — uveitis
Off-label
- Macular Degeneration
- Retinal Diseases
- Uveitis, Anterior
- Uveitis, Intermediate
- Uveitis, Posterior
Contraindications
Source: openFDA
- Ocular or Periocular Infections (4.1) Glaucoma (4.2) Hypersensitivity (4.3) 4.1 Ocular or Periocular Infections ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. 4.2 Glaucoma ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. 4.3 Hypersensitivity ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product. Absolute
Dosing
Source: openFDA
Warnings & Precautions
Source: openFDA
Warnings & Precautions
Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1) Intraocular Pressure (IOP) Increase : Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity, and fields of vision. (5.2) Cataracts : Use of corticosteroids may result in posterior subcapsular cataract formation. (5.3) Delayed Healing : The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. (5.4) Corneal and Scleral Melting : In those diseases causing thinning of the cornea or sclera, ophthalmic corticosteroids may lead to perforation of the globe. (5.5) Bacterial Infections : Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. (5.6) Viral Infections : Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). (5.7) Fungal Infections : Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. (5.8) Implant Migration : The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. (5.9)
Intravitreal Injection-related Effects Intravitreal injections, includ
Intravitreal Injection-related Effects Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. For patients with non-infectious uveitis affecting the posterior segment, hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection [see Patient Counseling Information (17) ] . Patients may experience temporary blurred vision after injection of the implant.
Intraocular Pressure (IOP) Increase Prolonged use of corticosteroids m
Intraocular Pressure (IOP) Increase Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment.
Cataracts The use of corticosteroids may result in posterior subcapsul
Cataracts The use of corticosteroids may result in posterior subcapsular cataract formation.
Delayed Corneal Wound Healing The use of corticosteroids after catarac
Delayed Corneal Wound Healing The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.
Corneal and Scleral Melting Various ocular diseases and long-term use
Corneal and Scleral Melting Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.
Bacterial Infections Prolonged use of corticosteroids may suppress the
Bacterial Infections Prolonged use of corticosteroids may suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.
Viral Infections Use of ocular corticosteroids may prolong the course
Viral Infections Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.
Fungal Infections Fungal infections of the cornea are particularly pro
Fungal Infections Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.
Risk of Implant Migration Patients in whom the posterior capsule of th
Risk of Implant Migration Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.
Chemistry & Properties
| Formula | C24H30F2O6 |
|---|---|
| Molecular weight | 452.49 g/mol |
| IUPAC name | (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| CAS | 67-73-2 |
| PubChem CID | 6215 |
| InChIKey | FEBLZLNTKCEFIT-VSXGLTOVSA-N |
| logP | 2.37 (XLogP 2.5) |
| Polar surface area | 93.06 Ų |
| H-bond acceptors / donors | 6 / 2 |
| Drug-likeness (QED) | 0.67 |
| Lipinski violations | 0 |
SMILES
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1Biology & Pharmacokinetics
Pharmacokinetics
| BBB penetrant | Yes |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2B6 | Inhibitor | — |
| CYP2C8 | Inhibitor | — |
| CYP3A4 | Inhibitor | — |
| CYP3A4 | Substrate | — |
Receptor binding (top 1)
| Target | Action | Affinity |
|---|---|---|
| Glucocorticoid receptor (NR3C1) | Agonist | pIC50 8.5 |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (16)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| proctolar center oint. | Ointment 2 %, 0.01 %, 0.25 %, 5 % | 15 g tube pack varies | Arab Center for Pharmaceuticals & Chemicals | 1.350 |
| Petralar Cream | Cream 0.025 % w/w | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 1.500 |
| Petralar Ointment | Ointment 0.025 % | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 1.500 |
| petralar N cream. | Cream 0.25 mg/g, 3.50 mg/g | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 1.500 |
| petralar N oint. | Ointment 0.25 mg/g, 3.50 mg/g | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 1.500 |
| Proctoheal New | Cream 0.1 mg/g, 20 mg/g | 15 g tube | Dar Al Dawa Development and Investment Co Ltd/Jordan | 1.720 |
| proctolar center supp | Suppository 0.1 mg, 5 mg, 100 mg, 40 mg | 10 | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 2.030 |
| Proctoheal New Supp | Suppository 0.1 mg, 40 mg | 10 | Dar Al Dawa Development and Investment Co Ltd/Jordan | 2.180 |
| proctolar center oint. | Ointment 2 %, 0.01 %, 0.25 %, 5 % | 30 g tube pack varies | Arab Center for Pharmaceuticals & Chemicals | 2.470 |
| Petralar Forte Cream | Cream 0.25 % w/w | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 2.500 |
| Petralar Forte Ointment | Ointment 0.25 % w/w | 15 g tube | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 2.500 |
| Procto synalar oint | Ointment 20 mg, 0.1 mg | 15 g tube | Nabulsi Drug Store | 2.790 |
| Synalar-N cream | Cream 0.025 %, 0.5 % | 15 g tube | Nabulsi Drug Store | 3.200 |
| Synalar-N ointment | Ointment 0.025 %, 0.5 % | 15 g tube | Nabulsi Drug Store | 3.200 |
| Procto synalar supp | Suppository 40 mg, 0.11 mg | 10 | Nabulsi Drug Store | 4.110 |
| Triderma | Cream 0.05 %, 4 %, 0.01 % | 30 g tube | PELLA PHARMACEUTICALS CO.LTD/JORDAN | 11.510 |